Halozyme Therapeutics, Inc. (HALO) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Halozyme Therapeutics’s revenue went from $147M in fiscal 2016 to $1.4B in fiscal 2025, growth of about 28.5% a year.
Net income in fiscal 2025 was $317M, a net margin of 22.7%; the best year in this period was 2024 with $444M.
Over the twelve months to September 30, 2026, revenue was $1.8B and net income $485M.
Free cash flow was $645M in fiscal 2025 and positive in 7 of the 10 years shown.
The diluted share count fell 3% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $1.4B | $1.0B | $829M | $660M | $443M | $268M | $196M | $152M | $317M | $147M |
| Gross profit | $1.5B | $1.2B | $856M | $637M | $521M | $362M | $224M | $150M | $142M | $285M | $113M |
| Operating income | $674M | $469M | $551M | $338M | $268M | $276M | $144M | -$68M | -$69M | $81M | -$83M |
| Net income | $485M | $317M | $444M | $282M | $202M | $403M | $129M | -$72M | -$80M | $63M | -$103M |
| EPS (diluted) | $4.01 | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 |
| R&D | — | $81M | $79M | $76M | $67M | $36M | $34M | $141M | $150M | $151M | $151M |
| Revenue growth | — | +37.5% | +22.4% | +25.6% | +48.9% | +65.7% | +36.5% | +29.1% | −52.0% | +115.8% | +8.6% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $898M | $652M | $479M | $389M | $240M | $299M | $55M | -$85M | -$50M | $134M | -$50M |
| Capital spending | -$12M | -$7M | -$11M | -$15M | -$5M | -$1M | -$3M | -$4M | -$5M | -$1M | -$3M |
| Free cash flow | $886M | $645M | $468M | $373M | $235M | $298M | $53M | -$89M | -$54M | $133M | -$54M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $400M | $342M | $250M | $402M | $200M | $350M | $150M | $200M | $0 | $0 | — |
| Stock-based pay | $68M | $52M | $43M | $37M | $24M | $21M | $17M | $35M | $36M | $31M | $26M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $134M | $116M | $118M | $363M | $741M | $368M | $421M | $58M | $169M | $67M |
| Debt | — | $2.2B | $1.5B | $1.5B | $1.5B | $879M | $402M | $409M | $126M | $202M | $217M |
| Equity | — | $49M | $364M | $84M | $170M | $197M | $151M | $92M | $249M | $208M | -$32M |
| Total assets | — | $2.5B | $2.1B | $1.7B | $1.8B | $1.1B | $580M | $566M | $440M | $520M | $262M |
| Shares (diluted) | 123M | 124M | 129M | 134M | 141M | 147M | 141M | 144M | 144M | 139M | 128M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 82.3% | 83.6% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% |
| Operating margin | 37.4% | 33.6% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | -34.5% | -45.6% | 25.6% | -56.7% |
| Net margin | 26.9% | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% |
| FCF margin | 49.1% | 46.2% | 46.1% | 45.0% | 35.6% | 67.2% | 19.8% | -45.6% | -35.7% | 41.9% | -36.5% |
| ROIC | — | 14.3% | 23.1% | 16.9% | 12.7% | 20.2% | 26.0% | -13.5% | -14.6% | 15.6% | -35.7% |
| ROE | — | 649.2% | 122.1% | 336.0% | 119.0% | 204.5% | 85.5% | -78.7% | -32.3% | 30.2% | 317.2% |
Frequently asked questions
What is Halozyme Therapeutics’s annual revenue?
$1.4B in fiscal 2025 and $1.8B over the twelve months to September 30, 2026.
How much profit does Halozyme Therapeutics make?
Net income was $317M in fiscal 2025 (net margin 22.7%).
Is Halozyme Therapeutics’s revenue growing?
Yes: revenue rose 37.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.